~~<i id='F00436BDE6'><strike id='F00436BDE6'><tt id='F00436BDE6'><pre id='F00436BDE6'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：focus 2025-09-28 01:38:34 - browse：88963

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： ReNAgade cuts staff seven months after raising $300 million

Wikipedia

focus

hotspot

focus

Wikipedia

hotspot

Themedicalcommunitytodayfacesadeceptivelysimplequestion:Howquicklyshouldweactwhenachild’slifeisonthe

WSS

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Chemotherapy drug shortage eases slightly but still widespread

AI can decode, harness the power of the humane immune system

3 questions for the future of Biden's cancer moonshot

30 years of 'Listening to Prozac'

ReNAgade cuts staff seven months after raising $300 million

focus

leisure time

Wikipedia

Supreme Court strikes down use of affirmative action

What to do when lifesaving products contribute to climate change

How to save PrEP access — and even expand it

VC firm General Catalyst wants to buy a health system

Apple is now the first public company to be valued at $3 trillion

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Drug repurposing or repositioning? The language matters

With clinical trial data readouts, here's how to spot spin

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senate panel eyes new effort on drug shortages

focus

As biotech industry slumps, bioscience job market is upside down

FDA panel signals lack of confidence in Amgen cancer drug data

The future of health care in the House

Pediatric cancer treatments threatened by a new FDA policy

Senate panel eyes new effort on drug shortages

Takeda, Janssen join wearable maker to measure scratching

hotspot

focus

Wikipedia

hotspot